iodine-131 epratuzumab

Iodine-131 epratuzumab is a radiolabeled antibody-drug conjugate composed of the humanized anti-CD22 monoclonal antibody epratuzumab conjugated to the radioisotope iodine-131. Epratuzumab targets CD22, a cell surface antigen expressed on B cells and overexpressed in most B-cell non-Hodgkin lymphomas. The drug delivers targeted beta radiation to malignant B cells via the attached iodine-131 isotope, resulting in DNA damage and cell death. This approach combines immunotherapy (antibody targeting) with radiopharmaceutical therapy (radioisotope-induced cytotoxicity). It was developed primarily for relapsed or refractory non-Hodgkin lymphoma and has also been studied for advanced solid tumors expressing CEA. The mechanism of action includes direct cytotoxicity from beta emissions as well as immune-mediated effects such as antibody-dependent cell-mediated cytotoxicity (ADCC)[1][2][6].

Other names

碘[131I]爱克妥昔单抗epratuzumab I-131